Page 93 - Drug Class Review

Drug Effectiveness Review Project

Drugs Authors: Burns et al. 39 Country: Multinational (9 countries) Eisai Inc., Teaneck, NJ and Eisai Co. Ltd., Tokyo, Japan To investigate the efficacy and safety of DON in a multinational setting in patients with mild to moderately severe AD Setting: Multi-center (82 clinical centers) placebo donepezil 10 mg donepezil 5 mg N/A 10 mg/d 5 mg/d 24 weeks 24 weeks 24 weeks 274 273 271 Fifty years of age or older; met DSM-III-R criteria for AD; met NINCDS/ADRDA for probable AD; MMSE scores between 10 and 26 (inclusive); CDR scores of 1 or 2 Patients with structural l

Alzheimer Year: 1999 Study design: RCT Sample size: 818

Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs